Table 2.
Details of numbers of samples and patients for SARS-CoV-2 cultivation (positive cultures/attempted) and days on which culturing attempted and successful.
| Numbers of samples and patients (culture positive/attempted) and associated sample incubation duration |
Days since symptom onset on which virus cultivation attempted |
Days since symptom onset on which virus culture positive |
|||||
|---|---|---|---|---|---|---|---|
| N culture positive samples/ N samples where culture attempted | N patients culture positive / N patients in whose samples culture was attempted | Duration (days) for which cultured cells incubated | First day attempted | Last day attempted (or further information) | Minimum | Maximum | |
| Studies including symptomatic period only | |||||||
| Basile | 56/234 (23.9%) | NR/195 | 5 | 0 | 29 | 0 | 18 |
| Bullard | 26/90 (28.9%) | NR | 4 | 0 | 21 | 0 | 7 |
| Decker | 2/2 (100%) | 1/1 (100.0%) | NR | Only attempted on days 18 and 21. | 18 | 21 | |
| Folgueira | 49/106 (46.2%) Mild: 18/50 Severe: 31/56 | NR/105 Mild: NR/50 Severe: NR/55 | 5 | 1 | At least day 32 | 1 | 10 (mild) 32 (severe) |
| Jeong | 3/9 (33.3%) (respiratory samples) | 2/5 (40.0%) | 4 | 8 | 30 | 11 | 15 |
| Kujawski | 13/17 (76.5%) respiratory samples) | 9/9 (100.0%) | NR | 0 | 8 | 0 | 8 |
| CDC unpublished (Midgley et al., Kujawski group) | Unclear from Figure | Unclear/14† | NR | 0 | 30 | 0 | 8 |
| L'Huillier | 12/23 (52.2%) | 12/23 (52.5%) | 6 | 0 | 5 | 1 | 5 |
| Liu | NR/NR | 1/1 (100%) | NR | NR | >18 days (exact days not reported) | NR | 18 |
| Perera | 16/68 (23.5%) | 16/35 (45.7%) | 6 days (72 h followed by an additional 72 h) | 0 | 67 | 0 | 7 |
| van Kampen | 62/690 (9.0%) | 23/129 (17.8%) | 7 days | 0 | 39 | 0 | 20 |
| Wölfel | 9/34 (26.5%) respiratory (43 samples in total)* | NR/9 | 6 days | 3 | 13 | 3 | 8 |
| Studies including pre-symptomatic and symptomatic period | |||||||
| Arons | 32/55 (58%) | 31/43 (72.1%) | NR | −7 | 13 | −6 | 13 (where all symptoms considered) 9 (fever, cough, shortness of breath only) |
| Singanayagam | 133/324 (41%) | 111/253 (44%) | Up to 14 days | −13 | 60 | −13 | 12 |
NR: Not reported.
⁎
Note that these figures are estimated from the number of markers displayed on Fig. 1d in Wölfel et al.; it is possible that the numbers are underestimated due to potential overlay of markers.
†
CDC unpublished data by Midgley et al. includes all patients included in Kujawski et al. plus 5 additional patients.